Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Change in Cash (2021 - 2025)

Historic Change in Cash for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to -$8.0 million.

  • Rxo's Change in Cash rose 6000.0% to -$8.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$17.0 million, marking a year-over-year decrease of 15666.67%. This contributed to the annual value of -$17.0 million for FY2025, which is 15666.67% down from last year.
  • Rxo's Change in Cash amounted to -$8.0 million in Q4 2025, which was up 6000.0% from $7.0 million recorded in Q3 2025.
  • Over the past 5 years, Rxo's Change in Cash peaked at $166.0 million during Q2 2022, and registered a low of -$99.0 million during Q4 2023.
  • Moreover, its 5-year median value for Change in Cash was $0.0 (2021), whereas its average is -$812500.0.
  • Its Change in Cash has fluctuated over the past 5 years, first tumbled by 435000.0% in 2022, then soared by 34000.0% in 2024.
  • Quarter analysis of 5 years shows Rxo's Change in Cash stood at -$2.0 million in 2021, then crashed by 4350.0% to -$89.0 million in 2022, then fell by 11.24% to -$99.0 million in 2023, then soared by 79.8% to -$20.0 million in 2024, then skyrocketed by 60.0% to -$8.0 million in 2025.
  • Its Change in Cash was -$8.0 million in Q4 2025, compared to $7.0 million in Q3 2025 and $3.0 million in Q2 2025.